Study #2022-0701
A Phase 2/3, multicenter, randomized, dose optimization (Part I), double-blind (Part II) study to compare the efficacy and safety of oral Azacitidine (Oral-Aza, ONUREG) plus best supportive care (BSC) versus placebo plus BSC in participants with IPSS-R low- or intermediate-risk Myelodysplastic Syndrome (MDS)
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.